FDA fast-tracks first drug nod under new national priority voucher program
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Now a test that offers new precision in prostate cancer detection
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
Subscribe To Our Newsletter & Stay Updated